# Safety and Efficacy Study of Switching From Epzicom to Truvada

> **NCT00724711** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 312 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
- **DRUG:** abacavir (ABC)/lamivudine (3TC)

## Key facts

- **NCT ID:** NCT00724711
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-04
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2012-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724711, "Safety and Efficacy Study of Switching From Epzicom to Truvada". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00724711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*